Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

59.25  +0.84 (+1.44%)

Premarket: 59.3 +0.05 (+0.08%)

Fundamental Rating

8

Taking everything into account, HALO scores 8 out of 10 in our fundamental rating. HALO was compared to 568 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make HALO suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
Each year in the past 5 years HALO has been profitable.
HALO had a positive operating cash flow in each of the past 5 years.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

HALO has a better Return On Assets (21.52%) than 98.94% of its industry peers.
Looking at the Return On Equity, with a value of 122.06%, HALO belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
HALO's Return On Invested Capital of 23.00% is amongst the best of the industry. HALO outperforms 99.12% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HALO is above the industry average of 14.25%.
The last Return On Invested Capital (23.00%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 21.52%
ROE 122.06%
ROIC 23%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

HALO has a better Profit Margin (43.74%) than 99.12% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
HALO has a better Operating Margin (54.32%) than 99.82% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
The Gross Margin of HALO (84.30%) is better than 86.97% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 54.32%
PM (TTM) 43.74%
GM 84.3%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for HALO has been reduced compared to 1 year ago.
Compared to 5 years ago, HALO has less shares outstanding
The debt/assets ratio for HALO has been reduced compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

HALO has an Altman-Z score of 4.75. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.75, HALO belongs to the best of the industry, outperforming 80.46% of the companies in the same industry.
The Debt to FCF ratio of HALO is 3.21, which is a good value as it means it would take HALO, 3.21 years of fcf income to pay off all of its debts.
HALO has a better Debt to FCF ratio (3.21) than 94.01% of its industry peers.
HALO has a Debt/Equity ratio of 4.14. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 4.14, HALO is not doing good in the industry: 83.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 4.14
Debt/FCF 3.21
Altman-Z 4.75
ROIC/WACC2.43
WACC9.45%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 7.80 indicates that HALO has no problem at all paying its short term obligations.
HALO has a better Current ratio (7.80) than 73.42% of its industry peers.
A Quick Ratio of 6.78 indicates that HALO has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.78, HALO is doing good in the industry, outperforming 67.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.8
Quick Ratio 6.78
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.16% over the past year.
The Earnings Per Share has been growing by 30.12% on average over the past years. This is a very strong growth
The Revenue has grown by 22.46% in the past year. This is a very strong growth!
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)52.16%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%53.66%
Revenue 1Y (TTM)22.46%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%29.55%

3.2 Future

The Earnings Per Share is expected to grow by 16.06% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.27% on average over the next years. This is quite good.
EPS Next Y24.79%
EPS Next 2Y26.9%
EPS Next 3Y24.66%
EPS Next 5Y16.06%
Revenue Next Year19.16%
Revenue Next 2Y21.57%
Revenue Next 3Y19.3%
Revenue Next 5Y11.27%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.01, which indicates a correct valuation of HALO.
Based on the Price/Earnings ratio, HALO is valued cheaper than 96.83% of the companies in the same industry.
When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (28.92), we can say HALO is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 11.22, the valuation of HALO can be described as reasonable.
Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 96.65% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (21.65), we can say HALO is valued slightly cheaper.
Industry RankSector Rank
PE 14.01
Fwd PE 11.22
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

HALO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HALO is cheaper than 96.30% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 96.13% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.63
EV/EBITDA 12.25
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 24.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y26.9%
EPS Next 3Y24.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HALO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/24/2025, 8:14:51 PM)

Premarket: 59.3 +0.05 (+0.08%)

59.25

+0.84 (+1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18 2025-02-18/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners99.23%
Inst Owner Change-0.08%
Ins Owners0.81%
Ins Owner Change0.77%
Market Cap7.32B
Analysts77.33
Price Target69.11 (16.64%)
Short Float %8.04%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.72%
Min EPS beat(2)6.64%
Max EPS beat(2)26.79%
EPS beat(4)4
Avg EPS beat(4)15.64%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)9.66%
EPS beat(16)13
Avg EPS beat(16)12.34%
Revenue beat(2)2
Avg Revenue beat(2)7.32%
Min Revenue beat(2)1.36%
Max Revenue beat(2)13.28%
Revenue beat(4)3
Avg Revenue beat(4)5.36%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)13.28%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)6
Avg Revenue beat(12)1.1%
Revenue beat(16)9
Avg Revenue beat(16)3.23%
PT rev (1m)2.48%
PT rev (3m)5.65%
EPS NQ rev (1m)1.44%
EPS NQ rev (3m)-9.94%
EPS NY rev (1m)5.59%
EPS NY rev (3m)6.05%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-10.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.39%
Valuation
Industry RankSector Rank
PE 14.01
Fwd PE 11.22
P/S 7.21
P/FCF 15.63
P/OCF 15.28
P/B 20.12
P/tB N/A
EV/EBITDA 12.25
EPS(TTM)4.23
EY7.14%
EPS(NY)5.28
Fwd EY8.91%
FCF(TTM)3.79
FCFY6.4%
OCF(TTM)3.88
OCFY6.55%
SpS8.22
BVpS2.95
TBVpS-3.68
PEG (NY)0.56
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 21.52%
ROE 122.06%
ROCE 28.66%
ROIC 23%
ROICexc 33.33%
ROICexgc 86.86%
OM 54.32%
PM (TTM) 43.74%
GM 84.3%
FCFM 46.13%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 4.14
Debt/FCF 3.21
Debt/EBITDA 2.38
Cap/Depr 13.15%
Cap/Sales 1.05%
Interest Coverage 52.2
Cash Conversion 75.71%
Profit Quality 105.47%
Current Ratio 7.8
Quick Ratio 6.78
Altman-Z 4.75
F-Score9
WACC9.45%
ROIC/WACC2.43
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)52.16%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%53.66%
EPS Next Y24.79%
EPS Next 2Y26.9%
EPS Next 3Y24.66%
EPS Next 5Y16.06%
Revenue 1Y (TTM)22.46%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%29.55%
Revenue Next Year19.16%
Revenue Next 2Y21.57%
Revenue Next 3Y19.3%
Revenue Next 5Y11.27%
EBIT growth 1Y62.13%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3Y32.05%
EBIT Next 5Y15.57%
FCF growth 1Y25.47%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y23.29%
OCF growth 3Y16.96%
OCF growth 5YN/A